Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Bristol-Myers Squibb Canada is pleased to announce that the Ontario government has made ERBITUX(TM) (cetuximab) available to patients suffering from metastatic colorectal cancer. This decision makes Ontario the second province, after British Columbia, to introduce funding for this important treatment option and represents encouraging news for those patients who rely on provincial drug coverage and stopped responding to standard treatments for metastatic colon cancer.

1 Oct 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Younger women with metastatic colorectal cancer live longer than younger men

Younger women with metastatic colorectal cancer lived longer than younger men. However, this survival advantage disappeared with age, suggesting a benefit from estrogen or other hormones, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

30 Sep 2009

MabCures develops monoclonal antibodies against Colorectal Cancer

MabCure, Inc., a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer (CRC). After further characterization the company plans to explore the utility of these MAbs in terms of both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.

29 Sep 2009

Response Genetics launches new genetic diagnostic test for gastric cancer

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the availability of its ResponseDX: Gastric™ genetic test panel, a proprietary PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal (GE) junction cancer.

29 Sep 2009

Phase 2 clinical trial results of IMO-2055 announced

Idera Pharmaceuticals, Inc., today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data are being presented during the Eighth International Kidney Cancer Symposium being held in Chicago, September 25-26, 2009.

28 Sep 2009

Careful follow-up after eradication therapy for peptic ulcer needed

Although it has been demonstrated that Helicobacter pylori causes gastric cancer, it is still controversial that whether H. pylori eradication therapy is effective in primary prevention of gastric cancer. This is especially important for Yamagata Prefecture, a region of Japan with the second highest incidence of gastric cancer in the world.

25 Sep 2009

Research study links cancer to excess body weight

At least 124,000 new cancers in 2008 in Europe may have been caused by excess body weight, according to estimates from a new modelling study. The proportion of cases of new cancers attributable to a body mass index of 25kg/m2 or more were highest among women and in central European countries such as the Czech Republic, Latvia, Slovenia and Bulgaria.

From The University of Manchester 24 Sep 2009

Results of Phase 3 CRYSTAL study of mCRC patients announced

The retrospective CRYSTAL analysis was conducted as a result of an effort to increase the tissue ascertainment rate to determine the K-ras status of patients’ tumors. The analysis included extended patient follow up of nearly 1.5 years and doubled the tissue ascertainment rate from 45% to 89%. These data are an update from the overall survival results from CRYSTAL that were published in the April 2009 issue of the New England Journal of Medicine.

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Patients with higher levels of vitamin D are less likely to die from skin cancer

New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients.

22 Sep 2009

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

AstraZeneca and Nektar Therapeutics announced today that they have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early stage programme that is intended to deliver products for the treatment of pain without constipation side effects.

21 Sep 2009

GI cancer detection simpler and cost-effective with new blood tests

Berlin, Germany: Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin today (Monday September 21). The tests will make GI cancer detection simpler, cost-effective, and more acceptable to patients than current methods, the researchers say.

21 Sep 2009

Study reveals that GI cancer can be diagnosed using blood tests

...

21 Sep 2009

Jennerex raises funds through private placement for clinical development programs

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced the Second and final closing of a private placement financing with aggregate gross proceeds of US $5,611,475, exceeding the target of US $5 million.

19 Sep 2009

Phase I trial of NPC-1C to commence

Neogenix Oncology, Inc. (Neogenix) announced today that NPC-1C, the company’s first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I trial.

18 Sep 2009

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Bristol-Myers announces availability of ERBITUX for metastatic colorectal cancer treatment

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Younger women with metastatic colorectal cancer live longer than younger men

MabCures develops monoclonal antibodies against Colorectal Cancer

Response Genetics launches new genetic diagnostic test for gastric cancer

Phase 2 clinical trial results of IMO-2055 announced

Careful follow-up after eradication therapy for peptic ulcer needed

Research study links cancer to excess body weight

Results of Phase 3 CRYSTAL study of mCRC patients announced

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Patients with higher levels of vitamin D are less likely to die from skin cancer

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

GI cancer detection simpler and cost-effective with new blood tests

Study reveals that GI cancer can be diagnosed using blood tests

Jennerex raises funds through private placement for clinical development programs

Phase I trial of NPC-1C to commence

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in